Drugs / human myeloid progenitor cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00891137 | Apr 2009 → Jun 2014 | leukemia, myelodysplastic syndrome, plasma cell myeloma | Cellerant Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01297543 | Mar 2011 → Nov 2014 | acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome | Cellerant Therapeutics | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | human myeloid progenitor cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00891137 ↗ |
| Modality | Cell therapy | “Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008)” NCT00891137 ↗ |
| Route | Intravenous | “Single intravenous injection/infusion” NCT00891137 ↗ |